A Computed Tomography-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study
Wei Wei,Zhenyu Liu,Yu Rong,Bin Zhou,Yan Bai,Wei Wei,Shuo Wang,Meiyun Wang,Yingkun Guo,Jie Tian
DOI: https://doi.org/10.3389/fonc.2019.00255
IF: 4.7
2019-04-09
Frontiers in Oncology
Abstract:Objectives: We used radiomic analysis to establish a radiomic signature based on preoperative contrast enhanced computed tomography (CT) and explore its effectiveness as a novel recurrence risk prognostic marker for advanced high-grade serous ovarian cancer (HGSOC).Methods: This study had a retrospective multicenter (two hospitals in China) design and a radiomic analysis was performed using contrast enhanced CT in advanced HGSOC (FIGO stage III or IV) patients. We used a minimum 18-month follow-up period for all patients (median 38.8 months, range 18.8–81.8 months). All patients were divided into three cohorts according to the timing of their surgery and hospital stay: training cohort (TC) and internal validation cohort (IVC) were from one hospital, and independent external validation cohort (IEVC) was from another hospital. A total of 620 3-D radiomic features were extracted and a Lasso-Cox regression was used for feature dimension reduction and determination of radiomic signature. Finally, we combined the radiomic signature with seven common clinical variables to develop a novel nomogram using a multivariable Cox proportional hazards model.Results: A final 142 advanced HGSOC patients were enrolled. Patients were successfully divided into two groups with statistically significant differences based on radiomic signature, consisting of four radiomic features (log-rank test P = 0.001, <0.001, <0.001 for TC, IVC, and IEVC, respectively). The discrimination accuracies of radiomic signature for predicting recurrence risk within 18 months were 82.4% (95% CI, 77.8–87.0%), 77.3% (95% CI, 74.4–80.2%), and 79.7% (95% CI, 73.8–85.6%) for TC, IVC, and IEVC, respectively. Further, the discrimination accuracies of radiomic signature for predicting recurrence risk within 3 years were 83.4% (95% CI, 77.3–89.6%), 82.0% (95% CI, 78.9–85.1%), and 70.0% (95% CI, 63.6–76.4%) for TC, IVC, and IEVC, respectively. Finally, the accuracy of radiomic nomogram for predicting 18-month and 3-year recurrence risks were 84.1% (95% CI, 80.5–87.7%) and 88.9% (95% CI, 85.8–92.5%), respectively.Conclusions: Radiomic signature and radiomic nomogram may be low-cost, non-invasive means for successfully predicting risk for postoperative advanced HGSOC recurrence before or during the perioperative period. Radiomic signature is a potential prognostic marker that may allow for individualized evaluation of patients with advanced HGSOC.
oncology